An Analysis Of Bleeding Risk In Endomyocardial Biopsy - Is Oral Anticoagulant Use Safe?
Transvenous endomyocardial biopsy (EMB) is an invasive procedure which is routinely used in the diagnosis of transplant rejection in patients with orthotopic heart transplant (OHT). EMB is generally regarded as safe, but bleeding complications have been described. It is unknown whether concomitant use of oral anticoagulants (OAC) increases the risk of bleeding in patients undergoing EMB, thus current clinical practice is variable regarding periprocedural anticoagulant continuation. The purpose of this study is to retrospectively evaluate bleeding complications amongst patients undergoing EMB while taking OAC. (Source: Jour...
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: James C. Stock, Jason Carlquist, Megan Melnyk, Jianing Ma, Jing Peng, Konstantinos D. Boudoulas, Rami Kahwash Tags: 099 Source Type: research
Impact Of New Allocation System On Length Of Stay Following Heart Transplantation: Insights From Unos Database
United Network for Organ Sharing (UNOS) allocation criteria changed in 2018 in order to accommodate the increased prevalence of patients on ventricular assist device as a bridge to heart transplant and prioritize sicker people in anticipation of a heart graft. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Ilias Doulamis, Athanasios Rempakos, Alexandros Briasoulis, Paulino Alvarez Tags: 100 Source Type: research
Patients With Lvads Had Worse Overall Survival After Simultaneous Heart-kidney Transplant As Compared To Patients Who Did Not Undergo Lvad Implantation Prior To Transplant
Many patients with advanced heart failure will develop chronic kidney disease (CKD) from cardiorenal syndrome, and some will progress to end-stage renal disease (ESRD) requiring dialysis. Several studies have demonstrated that patients with severe CKD or ESRD at the time of isolated orthotopic heart transplant (iOHT) have worse outcomes than those with normal renal function and in response, the incidence of simultaneous heart-kidney transplantation (sHKT) has increased. While several smaller studies suggest that sHKT is a safe option in patients with LVADs and renal dysfunction, recent literature demonstrated that these pa...
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Sakshi Gandhi, Allison Tzeng, Steven Hopkins, Eman Hamad Tags: 101 Source Type: research
Unplanned Hospital Admissions Stratification Model With Heart Failure Metrics: A Novel Approach For Measuring Disease Progression
Heart Failure (HF) is the leading cause of hospitalization for patients over 65, generating the highest rate of 30-day readmissions, accounting for 33% of all Fee for Service Medicare costs. Moreover, many instances of hospitalization for HF patients are considered preventable, making this group a perfect target for preventative care management programs (PCMP) aiming to improve outcomes and reduce costs by directly targeting avoidable and unplanned hospital admissions (UHAs). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Ravil Bikmetov, Juan Acosta, Zachary Finnel, Julie Santiago, David Priscal, Hymin Zucker, Noah Shreeve, Chris Koscho, Joseph Gartner, David DeCaprio, Gianfranco Bittar, Susana Acosta, Carol McCall Tags: 102 Source Type: research
Objectifying The Subjective: A Behavioral Health Risk Score To Be Utilized In The Selection Process Of Patients Seeking Advanced Heart Failure Therapies
Advanced heart failure therapies, heart transplantation (HT) and left ventricular assist device (LVAD) are limited due to scarcity of donors, expenses, and expansive lifetime care. Psychosocial determinants are persistently emphasized, but subjectively considered during the selection process. Described is our center's proof of concept utilizing a new behavioral/palliative consult system. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Sandra Carey, Johanna Van Zyl, Elizabeth Brown, Kenleigh McMinn, AnnMarie Warren Tags: 103 Source Type: research
Co-Administration of Inhibitors of HDAC6 and SGLT2 in Murine HFpEF Models Results in Additive Improvements in Cardiac Structural and Functional Measures
HFpEF is a form of heart failure characterized by diastolic dysfunction and associated with high morbidity, mortality and significant unmet need. Previously, we have demonstrated that selective inhibition of histone deacetylase 6 (HDAC6) has positive effects on diastolic dysfunction and left ventricular thickness of the heart, as well as overall improvements in systemic inflammation and metabolism, in a mouse model of HFpEF using a high-fat diet (HFD) and L-NAME. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA for HFpEF patients, works as expected in this model, confirming the potentia...
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Farshad Farshidfar, Aliya Zeng, Reva Shenwai, Matthew Kozubov, Iris Wu, Sara Ranjbarvaziri, Amara Greer-Short, Anastasiia Budan, Emma Xu, Cindy Li, Melissa Van Pell, Charles Mackay, Xiaomei Song, James Priest, Gretchen Argast, Jin Yang, Timothy Hoey Tags: 104 Source Type: research
Riluzole Mitigates The Risk Of Heart Failure Admissions
Targeting intracellular sodium accumulation through the late Na+ current modulates cardiac calcium handling, which underlies myocardial contractility and relaxation in heart failure (HF). This modulation has been recognized as a potential new early strategy in maintaining neurohormonal balance to evade acute heart failure (AHF). Riluzole (R) is an agent for management of amyotrophic lateral sclerosis (ALS). It promotes neuronal-type Na+ channel blockade and enhances Ca2+-activated K+ channel function. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Kibum Kim, Sodam Kim, Margaret Katana, Przemyslaw Radwanski, Mark A. Munger Tags: 105 Source Type: research
The Effect Of Concomitant Use Of Beta Blocker With Dobutamine During Hospitalization In Acute Heart Failure
Despite the contradictory action of mechanism, beta-blockers are often prescribed concomitantly with dobutamine during the treatment of acute heart failure (HF) in real clinical practice. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: MinJi Kim, Seo-Jung Ahn, Hee Jeong Lee, Seon-Hwa Lee, Hyungseop Kim, In-Cheol Kim Tags: 106 Source Type: research
An Echocardiographic Alert System To Identify Hospitalized Patients With Significant Mitral Regurgitation
Patients with significant primary or secondary mitral regurgitation (MR) may benefit from mitral valve surgery (MVS), medical therapy or transcatheter edge to edge repair (TEER). Although the prevalence of MR is significant, many patients do not receive treatment. A transthoracic echocardiogram (TTE) alert system to identify patients with significant MR has not been evaluated. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Ashley Yeung, David Shavelle, Merit Foley, Norman Guillen, Briana Cusolito, Carla Jean Lindenberg, Fernando Mendoza Tags: 107 Source Type: research
Improving Education On Discharge For Patients Admitted With Heart Failure
Heart failure (HF) remains a leading cause of hospitalization among US adults. Studies have shown that education decreases readmission rates and improves outcomes. The American Heart Association (AHA) created an educational booklet describing symptoms, treatments, and eating plans for heart failure. The goal of this project was to increase utilization of the AHA workbook in the form of discharge instructions to provide HF patients with valuable information. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Rachel Moshman, Diana Martirosyan, Jachrise Sibblis Tags: 108 Source Type: research
Reduced Heart Failure 30-day Readmission With Implementation Of A Cohesive And Structured Nurse Practitioner Led Inpatient And Outpatient Heart Failure Disease Management Program
There is reported relevance of multidisciplinary post discharge outpatient heart failure disease management (HFDM) programs in assisting to reduce the 30-day readmission. There is limited research showing the overall effect of a structured inpatient and post discharge heart failure outpatient program. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Andrea Creamer, Susan Bionat, Miriam delaflor Santa Ana, Robert Casey, Pinky Lauren Cabrera, Dora De Jesus, Cathy Williamson, Arvind Bhimaraj Tags: 109 Source Type: research
Multiparametric Response To Disease-Modifying Therapy For Transthyretin Amyloidosis Cardiomyopathy
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized condition with poor prognosis without treatment. The development of disease modifying therapies such as tafamidis has been shown to improve patient outcomes, but incorporation into clinical practice has been slow due in part to cost and lack of access. Targeting therapy to those experiencing the greatest benefit may help to alleviate these barriers to care, although indicators of a beneficial response to tafamidis has not been clearly defined. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Karan Shahi, Steven Dykstra, Patrick (Yuanchao) Feng, Jonathan Howlett, Shireen Kassam, Robert Miller, Jan Veenhuyzen, James White, Nowell Fine Tags: 110 Source Type: research
Double Trouble: A Case Of Biopsy Proven ATTR And AL Cardiac Amyloid
We present a very rare case of concomitant clinical and histology proven AL and ATTR amyloidosis. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Arianne Clare Agdamag, Shahzad Raza, Danai Dima, Rene Rodriguez, Deborah Kwon, Andrew Higgins, Trejeeve Martyn, J. Emanuel Finet, Wai Hong Tang, Mazen Hanna, Andres Carmona Rubio Tags: 111 Source Type: research
Validation Of The Transthyretin Amyloidosis Cardiomyopathy Score In A Black And Hispanic Screening Population: An Interim Analysis Of The First 342 Cases From The Scan-mp Study
The transthyretin amyloidosis cardiomyopathy (ATTR-CM) score was developed at the Mayo Clinic to identify high-risk patients for ATTR-CM. However, its performance in populations comprised of minoritized patients is unknown. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Nicholas Chan, Andrew Einstein, Sergio Teruya, Carlos Rodriguez, Stephen Helmke, Margaret Cuomo, Albert DeLuca, Lynne Johnson, Mona Kinkhabwala, Denisse Santana, Michelle Castillo, Dia Smiley, Natalia Sabogal, Sendy Lamour, Morgan Winburn, Denise Fine, Ci Tags: 112 Source Type: research
Pathogenic Transthyretin Gene Mutations In Phenotypic Hypertrophic Cardiomyopathy: An Underrecognized Double Whammy
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy with a prevalence of 1 in 500 patients. Genetic testing is generally recommended in order to differentiate between other cardiomyopathies with left ventricular (LV) hypertrophy such as hypertensive heart disease and cardiac amyloidosis (CA). Transthyretin cardiac amyloidosis (ATTR-CA) may occur either spontaneously or due to pathogenic gene mutations; in particular, the Val142Ile mutation may be present in as many as 3-4% of African American (AA) adults. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Varun Subashchandran, Anthony Kanelidis, Rachel Campagna, Gene Kim, Jeremy A. Slivnick Tags: 113 Source Type: research
